#United States #New York #Gross Law Firm #Securities Class Action #Sarepta Therapeutics

Alert for Sarepta Investors

The Gross Law Firm has recently issued a crucial notice for investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This serves as a reminder for shareholders who acquired shares during a specific period. If you are one of these investors, you may have a valuable opportunity to become involved in a class action lawsuit with ramifications that could potentially safeguard your investments against misleading corporate practices.

Class Period

The class period defined for this lawsuit spans from June 22, 2023, to June 24, 2025. Investors who have bought shares during this timeframe are strongly encouraged to reach out to the legal firm for more information regarding their potential eligibility for participation.

Key Allegations

The lawsuit alleges that Sarepta Therapeutics made several materially false statements and failed to disclose critical information about its gene therapy product, ELEVIDYS. The complaints indicate severe patient safety risks associated with this treatment. Key concerns outlined include:

• - Safety Risks: There are serious safety risks that were allegedly not disclosed to shareholders concerning the ELEVIDYS treatment. The firm claims that these omissions could have led investors to misconstrue the therapy's efficacy and safety profile.
• - Trial Protocol Failures: It is alleged that the trial procedures for ELEVIDYS did not adequately identify adverse side effects, leaving both investors and patients uninformed about the potential dangers.
• - Regulatory Concerns: Due to the serious adverse events linked to ELEVIDYS, the company may have to halt recruitment for trials and face increased scrutiny from regulatory bodies. This has the potential to jeopardize the product’s approval status.
• - Misleading Statements: The lawsuit contends that the executives of Sarepta issued positive statements about ELEVIDYS without a reasonable basis, thereby misleading investors. These statements eventually led to investors suffering financial losses.

Deadline Information

Importantly, the deadline to act in this class action lawsuit is approaching quickly. Investors interested in participating must register by August 25, 2025. The Gross Law Firm has simplified the registration process, allowing affected shareholders to sign up quickly to secure their position.

Next Steps for Investors

Once registered, shareholders will receive ongoing updates regarding the case's status through a dedicated portfolio monitoring software. This service provides added peace of mind as investors can remain informed throughout the process.

Why Choose the Gross Law Firm?

The Gross Law Firm is a nationally recognized legal entity specializing in class actions, particularly those concerning investor rights. Their commitment is to defend shareholders against any form of deceit or unlawful actions from corporations. By advocating for responsible business practices, they aim to ensure that companies like Sarepta Therapeutics uphold their duty to investors. The firm's reputation as a dedicated protector of investor rights makes it a trusted partner for those affected.

Contact Information

For more information, shareholders can reach out to The Gross Law Firm at their New York office:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In conclusion, if you are a Sarepta Therapeutics investor, now is the time to act in order to protect your interests and potentially recover losses related to misleading corporate conduct regarding its gene therapy product. Don't miss this opportunity to stand up for your rights as an investor. Contact The Gross Law Firm today to learn more about your eligibility and how to proceed with this important legal action.